Evidence map›Paper›PMID 20625113›Full record

ArticleCirculation2010

Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".

Selma F Mohammed, Tomohito Ohtani, Josef Korinek, Carolyn S P Lam, Katarina Larsen, Robert D Simari, Maria L Valencik, John C Burnett, Margaret M Redfield

Open access · bronzeAbstract read
In one paragraph

Article in Circulation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Sexual dimorphism in animal models of heart failure with preserved ejection fraction.Journal of applied physiology (Bethesda, Md. : 1985) · 2025
    Review
  3. Review
  4. Review
  5. Early pathological mechanisms in a mouse model of heart failure with preserved ejection fraction.American journal of physiology. Heart and circulatory physiology · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Endothelial cell dysfunction in cardiac disease: driver or consequence?Frontiers in cell and developmental biology · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Selma F MohammedCardiovascular Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Tomohito Ohtani
Josef Korinek
Carolyn S P Lam
Katarina Larsen
Robert D Simari
Maria L Valencik
John C Burnett
Margaret M Redfield
University of Nevada, Reno · US

Funding

MAYO CLINIC CENTER FOR TRANSLATIONAL SCIENCE ACTIVITIESUL1RR024150 · NCRR · MAYO CLINIC ROCHESTER · PI RIZZA, ROBERT A. · 2006 to 2011
$66.4M
Recruitment and Phenotyping CoreP01HL076611 · NHLBI · MAYO CLINIC ROCHESTER · PI BURNETT, JOHN C · 2005 to 2015
$19.6M
CARDIOVASOLOGYT32HL007111 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug · 1985 to 2026
$8.7M
ISOLATED DIASTOLIC DYSFUNCTIONR01HL063281 · NHLBI · MAYO CLINIC ROCHESTER · PI REDFIELD, MARGARET M · 2000 to 2008
$2.7M
NCRR NIH HHS 1 UL1 RR024150NCRR NIH HHS UL1 RR024150NHLBI NIH HHS HL-07111NHLBI NIH HHS HL-63281NHLBI NIH HHS HL-76611-1NHLBI NIH HHS P01 HL076611NHLBI NIH HHS R01 HL063281NHLBI NIH HHS T32 HL007111
6 · The paper itself

Abstract

backgroundMechanisms promoting the transition from hypertensive heart disease to heart failure with preserved ejection fraction are poorly understood. When inappropriate for salt status, mineralocorticoid (deoxycorticosterone acetate) excess causes hypertrophy, fibrosis, and diastolic dysfunction. Because cardiac mineralocorticoid receptors are protected from mineralocorticoid binding by the absence of 11-beta hydroxysteroid dehydrogenase, salt-mineralocorticoid-induced inflammation is postulated to cause oxidative stress and to mediate cardiac effects. Although previous studies have focused on salt/nephrectomy in accelerating mineralocorticoid-induced cardiac effects, we hypothesized that hypertensive heart disease is associated with oxidative stress and sensitizes the heart to mineralocorticoid, accelerating hypertrophy, fibrosis, and diastolic dysfunction. METHODS AND

resultsCardiac structure and function, oxidative stress, and mineralocorticoid receptor-dependent gene transcription were measured in sham-operated and transverse aortic constriction (studied 2 weeks later) mice without and with deoxycorticosterone acetate administration, all in the setting of normal-salt diet. Compared with sham mice, sham plus deoxycorticosterone acetate mice had mild hypertrophy without fibrosis or diastolic dysfunction. Transverse aortic constriction mice displayed compensated hypertensive heart disease with hypertrophy, increased oxidative stress (osteopontin and NOX4 gene expression), and normal systolic function, filling pressures, and diastolic stiffness. Compared with transverse aortic constriction mice, transverse aortic constriction plus deoxycorticosterone acetate mice had similar left ventricular systolic pressure and fractional shortening but more hypertrophy, fibrosis, and diastolic dysfunction with increased lung weights, consistent with heart failure with preserved ejection fraction. There was progressive activation of markers of oxidative stress across the groups but no evidence of classic mineralocorticoid receptor-dependent gene transcription.

conclusionsPressure-overload hypertrophy sensitizes the heart to mineralocorticoid excess, which promotes the transition to heart failure with preserved ejection fraction independently of classic mineralocorticoid receptor-dependent gene transcription.

Indexed as

AldosteroneAnimalsAtrial Natriuretic FactorCapillariesCollagenCytochrome b GroupDesoxycorticosteroneHeart FailureInflammationMaleMembrane GlycoproteinsMiceMice, Inbred StrainsMineralocorticoidsNADPH Oxidase 2NADPH Oxidase 4AldosteroneAtrial Natriuretic FactorCollagenCyba protein, mouseCybb protein, mouseCytochrome b GroupDesoxycorticosteroneMembrane GlycoproteinsMineralocorticoidsNADPH Oxidase 2NADPH Oxidase 4NADPH OxidasesNox4 protein, mouseOsteopontinRNARNA, Messenger

Identifiers

PMID20625113
PMCPMC2938025
OpenAlexW1977362120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.